Duchenne Muscular Dystrophy Market Report 2025

The duchenne muscular dystrophy market size has grown strongly in recent years. It will grow from $1.16 billion in 2024 to $1.26 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to genetic understanding and diagnostic advances, clinical trial progress, patient advocacy and awareness, orphan drug designation and incentives, collaborative research initiatives.

The duchenne muscular dystrophy market size is expected to see strong growth in the next few years. It will grow to $1.75 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to emerging gene therapies, precision medicine approaches, expanded access to therapies, long-term follow-up studies, regulatory advancements. Major trends in the forecast period include integration of digital health technologies, technological advancements in therapeutics, gene therapies and genetic medicines, regulatory support for orphan drugs, precision medicine approaches.

The rising prevalence of chronic diseases is expected to fuel the growth of the Duchenne muscular dystrophy market in the coming years. Chronic diseases, defined as health conditions with symptoms lasting a year or more, include Duchenne muscular dystrophy, which emphasizes the importance of targeted therapies to address the unique needs of individuals with this genetic disorder. This focus underlines the broader role of personalized medicine in managing and potentially reducing the impact of chronic conditions. For example, in January 2023, the National Library of Medicine, a U.S.-based government agency, projected that the number of Americans aged 50 and older with at least one chronic condition will increase to 142.66 million by 2050. Consequently, the rising prevalence of chronic diseases is anticipated to drive the Duchenne muscular dystrophy market forward.

The increasing demand for personalized medicine is expected to drive the growth of the Duchenne muscular dystrophy (DMD) market in the coming years. Personalized medicine customizes medical treatments based on an individual's unique genetic, environmental, and lifestyle factors, enhancing therapeutic precision and effectiveness. In the context of DMD, personalized medicine tailors treatments to specific patient needs, improving efficacy and overall health outcomes. For instance, in February 2023, the Personalized Medicine Coalition, a U.S.-based membership organization, reported that 12 new personalized medicines were approved in 2022, representing about 34% of all new therapies - a marked increase from previous years. This trend in personalized medicine is fueling growth in the DMD market by advancing tailored approaches to managing this genetic disorder.

Leading companies in the Duchenne muscular dystrophy (DMD) market are advancing technological solutions, such as enhanced clinical trial design, to streamline drug development, improve patient outcomes, and expedite the regulatory approval of new therapies. Clinical trial design involves systematically organizing trials to assess treatment safety and efficacy, including setting objectives, choosing participants, and determining analysis methods. For example, in March 2024, the Critical Path Institute (C-Path), a U.S.-based nonprofit, launched the DMD Clinical Trial Simulator (CTS). Developed by C-Path’s Duchenne Regulatory Science Consortium, this tool enhances the planning of DMD efficacy studies by offering features like performance modeling, scenario simulations, and trial efficiency improvements. Accessible through C-Path’s website and the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), the CTS aids researchers and pharmaceutical companies in optimizing clinical trials for DMD therapies, supporting the growth of innovation in the market.

Major players in the Duchenne muscular dystrophy market are directing their efforts towards product innovations, notably the development of the first gene therapy to treat Duchenne Muscular Dystrophy (DMD). This innovative therapy involves introducing functional copies of the dystrophin gene into affected individuals, aiming to correct the genetic mutation responsible for the progressive muscle degeneration associated with DMD. For instance, in June 2023, Sarepta Therapeutics, a US-based biopharmaceutical company specializing in RNA-based treatments for rare and infectious diseases, announced the FDA approval of ELEVIDYS, marking a significant milestone as the first gene therapy for Duchenne Muscular Dystrophy. This pioneering one-time treatment employs advanced gene therapy technology to target the root cause of the disease genetically. The approval of ELEVIDYS represents a paradigm shift in DMD treatment, moving beyond traditional supportive care approaches. It holds the potential to enhance patients' quality of life and life expectancy, showcasing the transformative impact of gene therapy on addressing rare diseases.

In December 2022, Solid Biosciences, a US-based life sciences company dedicated to advancing a portfolio of neuromuscular and cardiac programs, acquired AavantiBio for an undisclosed amount. This strategic acquisition positions the combined company to concentrate on the development of a diverse range of neuromuscular and cardiac programs, with a focus on advancing SGT-003, Solid's next-generation gene transfer candidate designed for the treatment of Duchenne muscular dystrophy. AavantiBio, Inc., a US-based biotechnology company, specializes in developing gene therapies aimed at transforming the lives of patients with rare genetic diseases.

Major companies operating in the duchenne muscular dystrophy market include Pfizer Inc., GlaxoSmithKline plc, PerkinElmer Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., WAVE Life Sciences Ltd., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc.

North America was the largest region in the Duchenne muscular dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in the duchenne muscular dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the duchenne muscular dystrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Duchenne muscular dystrophy is a genetic condition causing progressive muscle loss, impacting skeletal, cardiac, and lung muscles. It results from a mutation in the gene responsible for dystrophin production, a crucial protein for healthy muscle function.

Duchenne Muscular Dystrophy therapies involve mutation suppression and the exon skipping approach. Exon skipping, a prevalent form of alternative splicing, removes introns and intervals on a pre-mRNA molecule, typically functioning as exons of a gene, when forming the final mRNA. Therapeutic classes include molecular-based therapies and steroid therapy, administered through oral, parenteral, and other routes. These therapies are distributed via hospital pharmacies, online pharmacies, and retail pharmacies, serving end-users such as hospitals, homecare, specialty clinics, and others.

The duchenne muscular dystrophy market research report is one of a series of new reports that provides Duchenne muscular dystrophy optical components market statistics, including Duchenne muscular dystrophy optical components industry global market size, regional shares, competitors with a Duchenne muscular dystrophy optical components market share, detailed Duchenne muscular dystrophy optical components market segments, market trends, and opportunities, and any further data you may need to thrive in the Duchenne muscular dystrophy optical components industry. This Duchenne muscular dystrophy optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The duchenne muscular dystrophy market includes revenues earned by entities by providing respiratory therapy, physical therapy and gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.